MedTrace Logo

Registry of Patients Treated With Plerixafor (Mozobil®) for Haematopoietic Stem Cell Mobilization Before Autologous Transplantation

NCT01738373 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 262

Last updated 2015-03-23

No results posted yet for this study

Summary

The aim of this registry is to provide information, in day-to-day practice, on Plerixafor prescription modalities in France, over a 13-month period in order to address the health authorities' request.

Conditions

  • Bone Marrow / Autologous Transplants

Interventions

DRUG

Plerixafor

Plerixafor will be prescribed independently by the physician, according to usual practice.

Sponsors & Collaborators

  • Genzyme, a Sanofi Company

    lead INDUSTRY

Principal Investigators

  • Medical Monitor · Genzyme, a Sanofi Company

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-12-31
Primary Completion
2012-11-30
Completion
2012-11-30

Countries

  • France

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01738373 on ClinicalTrials.gov